Menu

Swedish Research Council: Macchiarini, Karolinska Skipped Ethical Review

The federal agency publishes a brief note alleging another ethical breach by former Karolinska Institute researcher Paolo Macchiarini.

May 3, 2016
Bob Grant

WIKIMEDIA, IJNMIS01A Swedish law in place since January 2004 regarding research conducted on human beings (including living people, cadavers, biological material from people, and sensitive personal information) requires that investigators conducting such work apply for ethical review. According to Anna Hörnlund, chief legal counsel at the Swedish Research Council, neither former Karolinska Institute researcher Paolo Macchiarini nor his former institution submitted an application before conducting such research. “The Swedish Research Council considers Paolo Macchiarini's activities to be research conducted in human beings,” Hörnlund wrote in The Lancet last week (April 30).

Also last week (April 28), the Karolinska Institute announced that it is investigating concerns about Macchiarini and colleagues’ 2015 Respiration paper on the administration of an experimental cellular treatment on a patient with acute respiratory distress syndrome. “I received the case on my desk last week. We have analyzed it and will demand answers from the researchers involved,” Henrik Grönberg, pro-vice-chancellor of the Karolinska Institute, said in the statement. “After that, we will decide if we will submit the matter for external review.”

Some of Macchiarini’s coauthors on a 2011 The Lancet paper last month asked to have their names removed from that study. The Karonliska Institute terminated its contract with Macchiarini in March.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.